FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Landry Robert E 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP Finance CFO
(Last)         (First)         (Middle)
777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)
6/29/2020
(Street)
TARRYTOWN, NY 10591
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/29/2020    S(1)    39  D $609.46 (2) 24334  D   
Common Stock  6/29/2020    S(1)    58  D $610.73 (3) 24276  D   
Common Stock  6/29/2020    S(1)    50  D $611.44 (4) 24226  D   
Common Stock  6/29/2020    S(1)    153  D $612.67 (5) 24073  D   
Common Stock  6/29/2020    S(1)    69  D $614.64 (6) 24004  D   
Common Stock  6/29/2020    S(1)    31  D $616.67  23973  D   
Common Stock                 200  I  By 401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2)  Represents volume-weighted average price of sales of 39 shares of Company stock on June 29, 2020 at prices ranging from $609.37 to $609.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price.
(3)  Represents volume-weighted average price of sales of 58 shares of Company stock on June 29, 2020 at prices ranging from $610.47 to $610.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price.
(4)  Represents volume-weighted average price of sales of 50 shares of Company stock on June 29, 2020 at prices ranging from $611.09 to $611.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price.
(5)  Represents volume-weighted average price of sales of 153 shares of Company stock on June 29, 2020 at prices ranging from $612.13 to $612.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price.
(6)  Represents volume-weighted average price of sales of 69 shares of Company stock on June 29, 2020 at prices ranging from $614.39 to $614.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Landry Robert E
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


EVP Finance CFO

Signatures
/s/**Robert E. Landry 6/30/2020
**Signature of Reporting Person Date
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Regeneron Pharmaceuticals Charts.